Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) 10-Year Financial Performance & Capital Metrics

CUPR • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutCuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company dedicated to developing and commercializing innovative products for managing chronic wounds. The company manufactures and distributes medical-grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand, used as a biological debridement tool for chronic wounds. Additionally, Cuprina operates in the health and beauty sectors, offering cosmeceutical products.Show more

Revenue $48K -52.0%
EBITDA -$2M -55.1%
Net Income -$2M -39.4%
EPS (Diluted) -0.07 -39.2%
Gross Margin -6.26% -117.2%
EBITDA Margin -3317.55% -223.6%
Operating Margin -3404.85% -221.2%
Net Margin -3229.52% -190.7%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -44.22 -134.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-6.18%

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-

EPS CAGR

10Y-

5Y-

3Y-

TTM-

ROCE

10Y Avg-

5Y Avg-

3Y Avg-

Latest-

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	58.5K	56.6K	100.77K	48.32K
Revenue Growth %	-	-0.03%	0.78%	-0.52%
Cost of Goods Sold+	35.45K	36.62K	64.17K	51.34K
COGS % of Revenue	0.61%	0.65%	0.64%	1.06%
Gross Profit+	23.06K	19.98K	36.6K	-3.02K
Gross Margin %	0.39%	0.35%	0.36%	-0.06%
Gross Profit Growth %	-	-0.13%	0.83%	-1.08%
Operating Expenses+	575.81K	1.2M	1.1M	1.64M
OpEx % of Revenue	9.84%	21.13%	10.96%	33.99%
Selling, General & Admin	248.19K	830.36K	833.45K	1.27M
SG&A % of Revenue	4.24%	14.67%	8.27%	26.27%
Research & Development	279.79K	292.88K	167.73K	241.36K
R&D % of Revenue	4.78%	5.17%	1.66%	4.99%
Other Operating Expenses	47.83K	72.53K	103.75K	131.62K
Operating Income+	-552.75K	-1.18M	-1.07M	-1.65M
Operating Margin %	-9.45%	-20.77%	-10.6%	-34.05%
Operating Income Growth %	-	-1.13%	0.09%	-0.54%
EBITDA+	-525.29K	-1.15M	-1.03M	-1.6M
EBITDA Margin %	-8.98%	-20.26%	-10.25%	-33.18%
EBITDA Growth %	-	-1.18%	0.1%	-0.55%
D&A (Non-Cash Add-back)	27.46K	29.09K	35.06K	42.19K
EBIT	-516.9K	-1.09M	-1.03M	-1.47M
Net Interest Income+	-2.78K	-2.02K	-56.59K	-37.21K
Interest Income	0	0	0	0
Interest Expense	2.78K	2.02K	56.59K	37.21K
Other Income/Expense	33.07K	88.62K	-17.44K	136.66K
Pretax Income+	-519.69K	-1.09M	-1.09M	-1.51M
Pretax Margin %	-8.88%	-19.21%	-10.77%	-31.22%
Income Tax+	0	7.34K	33.79K	51.93K
Effective Tax Rate %	1%	1.01%	1.03%	1.03%
Net Income+	-519.69K	-1.09M	-1.12M	-1.56M
Net Margin %	-8.88%	-19.34%	-11.11%	-32.3%
Net Income Growth %	-	-1.11%	-0.02%	-0.39%
Net Income (Continuing)	-519.69K	-1.09M	-1.12M	-1.56M
Discontinued Operations	0	0	0	0
Minority Interest	0	0	0	0
EPS (Diluted)+	-0.03	-0.05	-0.05	-0.07
EPS Growth %	-	-1.1%	0.04%	-0.39%
EPS (Basic)	-0.03	-0.05	-0.05	-0.07
Diluted Shares Outstanding	20.5M	20.5M	21.75M	21.75M
Basic Shares Outstanding	20.5M	20.5M	21.75M	21.75M
Dividend Payout Ratio	-	-	-	-

Balance Sheet

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	808.19K	1.27M	1.44M	1.66M
Cash & Short-Term Investments	767.29K	564.58K	35.26K	116.47K
Cash Only	767.29K	564.58K	35.26K	116.47K
Short-Term Investments	0	0	0	0
Accounts Receivable	19.52K	440.04K	211.88K	119.47K
Days Sales Outstanding	121.8	2.84K	767.45	902.47
Inventory	0	6.5K	7.67K	1.73K
Days Inventory Outstanding	-	64.8	43.6	12.3
Other Current Assets	14.49K	157.9K	1.04M	1.27M
Total Non-Current Assets+	144.86K	166.97K	150.65K	89K
Property, Plant & Equipment	144.86K	159.08K	150.65K	89K
Fixed Asset Turnover	0.40x	0.36x	0.67x	0.54x
Goodwill	0	0	0	0
Intangible Assets	0	0	0	0
Long-Term Investments	0	7.89K	0	0
Other Non-Current Assets	0	0	0	0
Total Assets+	953.05K	1.44M	1.59M	1.75M
Asset Turnover	0.06x	0.04x	0.06x	0.03x
Asset Growth %	-	0.51%	0.1%	0.1%
Total Current Liabilities+	1.51M	3.09M	4.43M	6.04M
Accounts Payable	220	0	0	0
Days Payables Outstanding	2.27	-	-	-
Short-Term Debt	19.46K	19.95K	20.85K	55.25K
Deferred Revenue (Current)	0	0	0	0
Other Current Liabilities	0	0	0	0
Current Ratio	0.54x	0.41x	0.32x	0.27x
Quick Ratio	0.54x	0.41x	0.32x	0.27x
Cash Conversion Cycle	-	-	-	-
Total Non-Current Liabilities+	127.28K	122.91K	57.51K	163.73K
Long-Term Debt	63.12K	43.17K	21.7K	163.73K
Capital Lease Obligations	64.15K	79.74K	35.81K	0
Deferred Tax Liabilities	0	0	0	0
Other Non-Current Liabilities	0	0	0	0
Total Liabilities	1.64M	3.21M	4.48M	6.2M
Total Debt+	170.03K	183.63K	121.82K	254.79K
Net Debt	-597.26K	-380.94K	86.56K	138.32K
Debt / Equity	-	-	-	-
Debt / EBITDA	-	-	-	-
Net Debt / EBITDA	-	-	-	-
Interest Coverage	-198.62x	-582.94x	-18.88x	-44.22x
Total Equity+	-683.52K	-1.78M	-2.9M	-4.46M
Equity Growth %	-	-1.6%	-0.63%	-0.54%
Book Value per Share	-0.03	-0.09	-0.13	-0.21
Total Shareholders' Equity	-683.52K	-1.78M	-2.9M	-4.46M
Common Stock	24.2K	24.2K	24.2K	24.2K
Retained Earnings	-786.45K	-1.88M	-3M	-4.56M
Treasury Stock	0	0	0	0
Accumulated OCI	0	-261	309	-1.59K
Minority Interest	0	0	0	0

Cash Flow

	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-221.86K	-1.85M	-1.54M	-1.24M
Operating CF Margin %	-3.79%	-32.68%	-15.31%	-25.58%
Operating CF Growth %	-	-7.34%	0.17%	0.2%
Net Income	-519.69K	-1.09M	-1.12M	-1.56M
Depreciation & Amortization	27.46K	29.09K	35.06K	42.19K
Stock-Based Compensation	0	0	0	0
Deferred Taxes	0	0	0	0
Other Non-Cash Items	4.58K	22.98K	64.79K	54.01K
Working Capital Changes	265.79K	-807.22K	-523.07K	228.36K
Change in Receivables	-18.8K	-38.25K	-35.02K	24.43K
Change in Inventory	0	-6.5K	-1.16K	0
Change in Payables	-2.03K	-220	0	0
Cash from Investing+	-2.86K	-31.28K	-67.98K	-21.88K
Capital Expenditures	-2.86K	-16.05K	-67.98K	-21.88K
CapEx % of Revenue	0.05%	0.28%	0.67%	0.45%
Acquisitions	-	-	-	-
Investments	-	-	-	-
Other Investing	0	0	0	0
Cash from Financing+	991.39K	1.68M	1.08M	1.34M
Debt Issued (Net)	-	-	-	-
Equity Issued (Net)	-	-	-	-
Dividends Paid	0	0	0	0
Share Repurchases	-	-	-	-
Other Financing	908.81K	1.7M	1.1M	1.16M
Net Change in Cash	-	-	-	-
Free Cash Flow+	-224.72K	-1.87M	-1.61M	-1.26M
FCF Margin %	-3.84%	-32.96%	-15.98%	-26.03%
FCF Growth %	-	-7.3%	0.14%	0.22%
FCF per Share	-0.01	-0.09	-0.07	-0.06
FCF Conversion (FCF/Net Income)	0.43x	1.69x	1.38x	0.79x
Interest Paid	2.78K	2.02K	727	221
Taxes Paid	0	0	0	0

Key Ratios

Metric	2021	2022	2023	2024
Gross Margin	39.41%	35.3%	36.32%	-6.26%
Net Margin	-888.29%	-1933.81%	-1110.97%	-3229.52%
Interest Coverage	-198.62x	-582.94x	-18.88x	-44.22x
FCF Conversion	0.43x	1.69x	1.38x	0.79x
Revenue Growth	-	-3.26%	78.05%	-52.05%

Frequently Asked Questions

Growth & Financials

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) reported $0.0M in revenue for fiscal year 2024. This represents a 17% decrease from $0.1M in 2021.

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) saw revenue decline by 52.0% over the past year.

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) reported a net loss of $1.6M for fiscal year 2024.

Dividend & Returns

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) had negative free cash flow of $1.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener